Scarica l'app Stockscreener
91.61
1.55%
1.40
Pre-mercato:
91.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CORT Giù?
Forum
Previsione
Precedente Chiudi:
$90.21
Aprire:
$90.29
Volume 24 ore:
1.17M
Relative Volume:
1.03
Capitalizzazione di mercato:
$9.83B
Reddito:
$769.10M
Utile/perdita netta:
$46.67M
Rapporto P/E:
261.74
EPS:
0.35
Flusso di cassa netto:
$119.79M
1 W Prestazione:
+4.23%
1M Prestazione:
+26.15%
6M Prestazione:
+156.04%
1 anno Prestazione:
+26.76%
Intervallo 1D:
$89.73
$92.83
Intervallo di 1 settimana:
$86.04
$92.83
Portata 52W:
$28.66
$92.83
Corcept Therapeutics Inc Stock (CORT) Company Profile
Nome
Corcept Therapeutics Inc
Settore
Industria
Telefono
650.688.8803
Indirizzo
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
91.61 | 9.33B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-05-13 | Aggiornamento | UBS | Neutral → Buy |
| 2026-03-26 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | Iniziato | UBS | Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-06 | Aggiornamento | Truist | Hold → Buy |
| 2023-04-11 | Iniziato | SVB Securities | Market Perform |
| 2023-04-04 | Iniziato | Piper Sandler | Overweight |
| 2023-02-15 | Downgrade | Jefferies | Buy → Hold |
| 2022-08-01 | Downgrade | Truist | Buy → Hold |
| 2022-07-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-06-27 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-02 | Iniziato | Canaccord Genuity | Buy |
| 2022-01-28 | Iniziato | Truist | Buy |
| 2020-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-09-24 | Iniziato | Jefferies | Buy |
| 2019-09-06 | Iniziato | H.C. Wainwright | Buy |
| 2019-02-04 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | Reiterato | Stifel | Hold |
| 2018-05-31 | Downgrade | Stifel | Buy → Hold |
| 2018-03-09 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | Iniziato | Stifel | Buy |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2015-04-21 | Iniziato | FBR Capital | Outperform |
| 2014-01-13 | Downgrade | Stifel | Buy → Hold |
| 2013-08-09 | Downgrade | Janney | Buy → Neutral |
| 2013-08-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-01-06 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | Iniziato | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | Aggiornamento | Punk, Ziegel & Co | Mkt Perform → Accumulate |
Mostra tutto
Corcept Therapeutics Inc Borsa (CORT) Ultime notizie
CORTCorcept Therapeutics Inc Volatility & Greeks - Finviz
Price to sales forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
CORT Stock Hits Highest Levels In 2026 – Cushing’s Syndrome Drug NDA Resubmission Extends 5-Session Rally - Stocktwits
Enterprise value to revenue forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Price to earnings forward of Corcept Therapeutics Incorporated – NASDAQ:CORT - TradingView
Corcept sinks after FDA rejects drug to treat hypertension - MSN
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Growth-Defensive Index - marketscreener.com
Corcept Therapeutics Incorporated(NasdaqCM:CORT) dropped from Russell 1000 Defensive Index - marketscreener.com
CORT Stock Slips After-Hours On Weak Q4 Print: Retail Is Watching April FDA Meeting For Relacorilant As Next Catalyst - Stocktwits
CORT Stock Skyrockets 35% After Early FDA Nod For Ovarian Cancer Drug - Stocktwits
Corcept gives FDA new relacorilant data in resubmitted application - Cushing's Disease News
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm - PR Newswire
Number of shareholders of Corcept Therapeutics Incorporated. – BX:HTD - TradingView
Corcept Therapeutics Incorporated. Actuals & Estimates (NASDAQ:CORT) - TradingView
HTD Forecast — Price Target — Prediction for 2027 - TradingView
Corcept Therapeutics Inc (CORT) Institutional Confidence - TradingKey
Corcept Therapeutics Inc (CORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corcept Therapeutics Inc (CORT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CORT News | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Corcept Therapeutics Inc (CORT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Corcept Therapeutics Inc (CORT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Corcept Therapeutics Inc (CORT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trust linked to Corcept (NASDAQ: CORT) director sells 10,000 shares in plan - Stock Titan
Corcept (CORT) director’s entities report 20K-share sale and large holdings - Stock Titan
Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peer Perf - GuruFocus
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Corcept Therapeutics Inc (CORT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome - Business Wire
Corcept Therapeutics Inc (CORT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Corcept Therapeutics (CORT) Resubmits NDA for Relacorilant with New Data - GuruFocus
Corcept Therapeutics (CORT) Resubmits Drug Application for Cushi - GuruFocus
Corcept Therapeutics (CORT) resubmits FDA NDA for relacorilant in Cushing’s syndrome - Stock Titan
Corcept Therapeutics(CORT.US) Officer Sells US$3.25 Million in Common Stock - Moomoo
Corcept Therapeutics (CORT) CFO exercises options, sells 40,000 shares in 10b5-1 trades - Stock Titan
Charles Schwab (NASDAQ: CORT) files Form 144 listing 20,000 shares - Stock Titan
[144] CORCEPT THERAPEUTICS INC SEC Filing - Stock Titan
Korlym improves results for diabetes patients taking GLP-1 drugs - Cushing's Disease News
Catalyst and Momentum Trials Data Fuels Optimism for Corcept Therapeutics (CORT) - Yahoo Finance
Norges Bank Purchases New Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Clearbridge Investments LLC Has $17.66 Million Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
CORT to resubmit NDA for relacorilant in Cushing's syndrome, stock up - MSN
7 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
CORT Stock Rises 42% in a Month: Here's What You Should Know - The Globe and Mail
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diab - GuruFocus
Corcept Therapeutics (CORT) Reveals Promising Trial Data on Diabetes Treatment - GuruFocus
Geode Capital Management LLC Acquires 734,646 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® - Lelezard
Corcept Therapeutics Inc Azioni (CORT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Corcept Therapeutics Inc Azioni (CORT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MAHONEY DAVID L | Director |
Jun 17 '26 |
Sale |
84.53 |
20,000 |
1,690,506 |
26,147 |
| Mokari Atabak | Chief Financial Officer |
Jun 15 '26 |
Option Exercise |
19.26 |
40,000 |
770,400 |
56,130 |
| Mokari Atabak | Chief Financial Officer |
Jun 15 '26 |
Sale |
81.15 |
40,000 |
3,245,900 |
16,130 |
0.05%
0.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):